Page 1

MedinCell MedinCell publishes its financial results and activity report for the first half of 2021-2022 ( April - September 2021 ) Euronext : MEDCL • Montpellier - France • December 8 , 2021 • 5:45 pm ( CET ) Revenue : € 4.1 million ( + 30 % compared with the first half of the previous year ) Operating expenses : € 15.3 million ( + 36 % ) Cash consumption from operations : € 11.3 million Available cash : € 34.4 million in cash + € 3.0 million in non - risky financial assets ( € 2.9 million current + € 0.1 million non - current ) Post - closing ( November 2021 ) € 3.1 million received in Research Tax Credit + € 3.0 million loan received from Bpifrance + € 1.0 million , partially collected , as a grant within the framework of the French Recovery Plan ( Plan France Relance ) mdc - IRM ( schizophrenia ) : marketing planned from 2022 by Teva in the United States , subject to FDA approval • . FDA acceptance of New Drug Application for mdc - IRM for treatment of patients with schizophrenia in August 2021 Phase 3 data for mdc - IRM , presented by Teva Pharmaceuticals at Psych Congress ( October 30 - November 1 , 2021 ) , shows significant improvements for patients with schizophrenia : prolonged time to impending relapse , decreased risk of relapse and increased chance of clinical stability Portfolio of products based on BEPO® technology in regulatory development as of December 1 , 2021 mdc - GRT Tacrolimus Organ Transplant mdc - TTG Ivermectin Covid - 19 mdc - WWM Progestin ( non - MPA ) Contraception mdc - ANG Confidential Schizophrenia mdc - STM Ivermectin Malaria mdc - KPT Confidential Pain Preclinical mdc - CWM Celecoxib Pain & inflammation mdc - TJK Confidential Schizophrenia mdc - IRM Risperidone Schizophrenia Clinical phase 3 NDA ( New Drug Application ) Clinical phase 1/2 In partnership with AIC Supported by Unitaid Internal programs In partnership with Teva Pharmaceuticals Supported by the Bill & Melinda Gates Foundation Animal Health product ( different clinical development process ) 1/6 Market